Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pharmaseek

Neither a doctor nor a teaching hospital

Research payments

$9,079,368

471 payments

Through program year 2025, Pharmaseek is reported as receiving $9,079,368 in research payments, across 471 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,102,622 44
2024 Research $889,185 65
2023 Research $2,163,727 72
2022 Research $131,782 16
2021 Research $44,046 23
2020 Research $4,471,682 161
2019 Research $276,324 90

Breakdown

Who paid Research payments · program years 2019–2025
  1. Romark Laboratories, LC $4,256,716 50 payments
  2. AstraZeneca Pharmaceuticals LP $1,589,970 15 payments
  3. E.R. Squibb & Sons, L.L.C. $881,505 17 payments
  4. GlaxoSmithKline, LLC. $754,596 36 payments
  5. Celgene Corporation $524,365 22 payments
  6. Janssen Research & Development, LLC $479,992 106 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $288,117 212 payments
  8. Novartis Pharmaceuticals Corporation $276,551 7 payments
  9. Ipsen Innovation $13,298 2 payments
  10. UCB Biosciences Inc. $7,500 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19 $1,971,072 12 payments
  2. Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $1,335,860 12 payments
  3. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $1,315,212 9 payments
  4. A Phase 1/2, First-Time-In Human (Ftih), Randomized, Observer-Blind, P $703,494 15 payments
  5. A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years $468,492 105 payments
  6. A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza $457,274 8 payments
  7. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection $409,010 5 payments
  8. A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia $382,816 9 payments
  9. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia $348,211 5 payments
  10. a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton $211,566 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record